Vantis Vascular has announced the first commercial use of its CrossFAST integrated microcatheter advanced delivery system in a series of 10 successful complex high-risk coronary interventional procedures (CHiP). The first case was performed by Amir Kaki at St John’s Hospital in Detroit, USA.
“CHiP procedures often involve patients with multiple comorbidities, tortuous anatomy and significant disease, requiring specialised tools to deliver percutaneous therapies,” commented Kaki. “The CrossFAST advanced delivery system performed exceptionally well due to its ability to safely and efficiently navigate tight, highly calcified vessels. Despite the challenging anatomy, CrossFAST was easily advanced, enabling stent delivery to the lesion which otherwise would have been difficult and time-consuming. This advanced delivery system is whole new class of device that exceeds performance of traditional guide extensions making this a welcomed tool in the complex operator’s toolbox.”
Results from the initial clinical use of the CrossFAST system demonstrated 100% procedural success with quick and reliable delivery to the target location, successful stent delivery and no device-related complications. Superior deliverability was noted during several highly complex cases where a traditional guide extension catheter failed to reach the target lesion and was swapped out for the CrossFAST system, which was delivered with ease, a press release from Vantis Vascular states.
The CrossFAST system is the first and only dual monorail microcatheter advanced delivery system purpose-built for complex coronary and peripheral interventions, the company claims.
Unlike guide extension catheters, which have limited ability to reach targeted areas in high-risk percutaneous coronary intervention (PCI) and demonstrated risk of vessel trauma and damage to previously placed stents, the CrossFAST advanced delivery system incorporates an integrated microcatheter with a seamless transition to lower the risk of these adverse events during catheter delivery.
The CrossFAST system is powered by DuoPRO interlocking technology, a novel mechanism coupling the microcatheter to the outer delivery catheter, allowing the system to be advanced as one unit for enhanced pushability and efficient navigation, a significant limitation of guide extension catheters, especially in complex high-risk procedures.
“We are thrilled with the early performance of the CrossFAST system,” said Frank Saltiel, chief clinical officer at Vantis Vascular. “The device’s ability to navigate complex coronary anatomy with ease has the potential to revolutionise the way we approach CHiP procedures. We are confident that CrossFAST will play a crucial role in advancing coronary therapy by decreasing procedure times and reducing complications in patients with complex, difficult-to-treat lesions.”
The CrossFAST integrated microcatheter advanced delivery system is commercially available in the USA as part of a limited market release. Full market release is planned for later in 2025.
